公开(公告)号：AU3646299A

公开(公告)日：1999-11-01

申请号：AU3646299

申请日：1999-04-15

Applicant: COR THERAPEUTICS INC

Inventor： LAW DEBORAH ANN ,  PHILLIPS DAVID R

IPC: A01K67/027 ,  A61K45/00 ,  A61P7/02 ,  C07K14/705 ,  C12N15/09 ,  C12N15/85 ,  C12N5/10 ,  A61K49/00

公开(公告)号：CA2325817A1

公开(公告)日：1999-10-21

申请号：CA2325817

申请日：1999-04-15

Applicant: COR THERAPEUTICS INC

Inventor： LAW DEBORAH ANN ,  PHILLIPS DAVID R

IPC: A01K67/027 ,  A61K45/00 ,  A61P7/02 ,  C07K14/705 ,  C12N15/09 ,  C12N15/85 ,  C12N5/10 ,  A61K49/00

Abstract: The present invention relates to mammals into which foreign DNA has been introduced or in which various modifications or substitutions have been made to an integrin .beta. subunit, thereby generating transgenic or geneticallyengineered non-human mammals. In particular, the present invention provides a transgenic mammal in which the endogenous GP IIIa gene has been replaced with an altered or mutant GP IIIa gene in which one or all of the phosphorylatable cytoplasmic tyrosine residues have been replaced with non-tyrosine residues such as phenylalanine. Since the platelets in the blood of the resultant transgenic mammals expressing the altered or mutant GP IIIa cannot undergo tyrosine phosphorylation to the extent that it occurs in wild-type mammals, these genetically-engineered animals provide a critical tool for assessing the importance of the phosphorylation reaction for platelet function. The invention is also useful for studying the effect of the mutant GP IIIa integrin subunit on biological processes other than platelet formation.

公开(公告)号：MX9704546A

公开(公告)日：1997-10-31

申请号：MX9704546

申请日：1996-10-18

Applicant: COR THERAPEUTICS INC

Inventor： PHILLIPS DAVID R ,  LAW DEBORAH ANN ,  ALAIMO LISA HANNIZZI

IPC: G01N33/53 ,  A61K38/00 ,  A61K45/00 ,  A61P7/02 ,  A61P9/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/705 ,  C12N5/06 ,  C12N11/02 ,  C12N15/09 ,  A61K39/00 ,  A61K39/38 ,  G01N33/574 ,  A01N37/18

Abstract: La presente invencion describe que la fosforilacion de los residuos de tirosina citoplásmicos en la subunidad beta de las integrinas es necesaria para la asociacion de la proteína de señal. La invencion proporciona métodos para identificar las parejas de transmision de señales comprendidas en la transmision de señales mediadas por integrinas, métodos para identificar los agentes que bloquean la transmision de señales mediadas por integrinas, métodos para usar agentes que bloquean la transmision de señales mediada por integrinas para modular los procesos biologicos y patologicos, y agentes que bloquean la transmision de señales mediadas por integrinas.

公开(公告)号：CA2207973A1

公开(公告)日：1997-04-24

申请号：CA2207973

申请日：1996-10-18

Applicant: COR THERAPEUTICS INC

Inventor： ALAIMO LISA NANNIZZI ,  LAW DEBORAH ANN ,  PHILLIPS DAVID R

IPC: G01N33/53 ,  A61K38/00 ,  A61K45/00 ,  A61P7/02 ,  A61P9/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/705 ,  C12N5/06 ,  C12N11/02 ,  C12N15/09 ,  A61K38/17 ,  C12Q1/48 ,  G01N33/573

Abstract: The present invention discloses that phosphorylation of cytoplasmic tyrosine residues in the .beta.-subunit of integrins is needed for signal protein association. The invention provides methods of identifying signaling partners involved in integrin mediated signaling, methods of identifying agents which block integrin mediated signaling, methods of using agents which block intergrin mediated signaling to modulate biological and pathological processes, and agents which block integrin mediated signaling.